611 related articles for article (PubMed ID: 21366473)
1. Long-term effects of intensive glucose lowering on cardiovascular outcomes.
; Gerstein HC; Miller ME; Genuth S; Ismail-Beigi F; Buse JB; Goff DC; Probstfield JL; Cushman WC; Ginsberg HN; Bigger JT; Grimm RH; Byington RP; Rosenberg YD; Friedewald WT
N Engl J Med; 2011 Mar; 364(9):818-28. PubMed ID: 21366473
[TBL] [Abstract][Full Text] [Related]
2. Effects of intensive glucose lowering in type 2 diabetes.
; Gerstein HC; Miller ME; Byington RP; Goff DC; Bigger JT; Buse JB; Cushman WC; Genuth S; Ismail-Beigi F; Grimm RH; Probstfield JL; Simons-Morton DG; Friedewald WT
N Engl J Med; 2008 Jun; 358(24):2545-59. PubMed ID: 18539917
[TBL] [Abstract][Full Text] [Related]
3. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
Reaven PD; Emanuele NV; Wiitala WL; Bahn GD; Reda DJ; McCarren M; Duckworth WC; Hayward RA;
N Engl J Med; 2019 Jun; 380(23):2215-2224. PubMed ID: 31167051
[TBL] [Abstract][Full Text] [Related]
4. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
[TBL] [Abstract][Full Text] [Related]
5. Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
[TBL] [Abstract][Full Text] [Related]
6. Effects of intensive blood-pressure control in type 2 diabetes mellitus.
; Cushman WC; Evans GW; Byington RP; Goff DC; Grimm RH; Cutler JA; Simons-Morton DG; Basile JN; Corson MA; Probstfield JL; Katz L; Peterson KA; Friedewald WT; Buse JB; Bigger JT; Gerstein HC; Ismail-Beigi F
N Engl J Med; 2010 Apr; 362(17):1575-85. PubMed ID: 20228401
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.
Hayward RA; Reaven PD; Wiitala WL; Bahn GD; Reda DJ; Ge L; McCarren M; Duckworth WC; Emanuele NV;
N Engl J Med; 2015 Jun; 372(23):2197-206. PubMed ID: 26039600
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP; Bain SC; Consoli A; Eliaschewitz FG; Jódar E; Leiter LA; Lingvay I; Rosenstock J; Seufert J; Warren ML; Woo V; Hansen O; Holst AG; Pettersson J; Vilsbøll T;
N Engl J Med; 2016 Nov; 375(19):1834-1844. PubMed ID: 27633186
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
10. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Margolis KL; O'Connor PJ; Morgan TM; Buse JB; Cohen RM; Cushman WC; Cutler JA; Evans GW; Gerstein HC; Grimm RH; Lipkin EW; Narayan KM; Riddle MC; Sood A; Goff DC
Diabetes Care; 2014 Jun; 37(6):1721-8. PubMed ID: 24595629
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ;
N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
[TBL] [Abstract][Full Text] [Related]
14. Glucose targets for preventing diabetic kidney disease and its progression.
Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
; Wing RR; Bolin P; Brancati FL; Bray GA; Clark JM; Coday M; Crow RS; Curtis JM; Egan CM; Espeland MA; Evans M; Foreyt JP; Ghazarian S; Gregg EW; Harrison B; Hazuda HP; Hill JO; Horton ES; Hubbard VS; Jakicic JM; Jeffery RW; Johnson KC; Kahn SE; Kitabchi AE; Knowler WC; Lewis CE; Maschak-Carey BJ; Montez MG; Murillo A; Nathan DM; Patricio J; Peters A; Pi-Sunyer X; Pownall H; Reboussin D; Regensteiner JG; Rickman AD; Ryan DH; Safford M; Wadden TA; Wagenknecht LE; West DS; Williamson DF; Yanovski SZ
N Engl J Med; 2013 Jul; 369(2):145-54. PubMed ID: 23796131
[TBL] [Abstract][Full Text] [Related]
16. Basal insulin and cardiovascular and other outcomes in dysglycemia.
; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
[TBL] [Abstract][Full Text] [Related]
17. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
[TBL] [Abstract][Full Text] [Related]
18. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA; Claggett B; Diaz R; Dickstein K; Gerstein HC; Køber LV; Lawson FC; Ping L; Wei X; Lewis EF; Maggioni AP; McMurray JJ; Probstfield JL; Riddle MC; Solomon SD; Tardif JC;
N Engl J Med; 2015 Dec; 373(23):2247-57. PubMed ID: 26630143
[TBL] [Abstract][Full Text] [Related]
19. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Husain M; Birkenfeld AL; Donsmark M; Dungan K; Eliaschewitz FG; Franco DR; Jeppesen OK; Lingvay I; Mosenzon O; Pedersen SD; Tack CJ; Thomsen M; Vilsbøll T; Warren ML; Bain SC;
N Engl J Med; 2019 Aug; 381(9):841-851. PubMed ID: 31185157
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
